First draft prepared by A . Bartholomaeus Office of Chemical Safety Therapeutic Goods

Explanation.................................................................................................... 275 Evaluation for acceptable daily intakes ........................................................ 276 Biochemical aspects ................................................................................ 277 Absorption distribution and excretion ............................................... 277 Oral administration....................................................................... 277 Dermal application ....................................................................... 279 Biotransformation .............................................................................. 280 Toxicological studies ............................................................................... 282 Acute toxicity ..................................................................................... 282 Oral administration....................................................................... 282 Dermal irritation........................................................................... 283 Ocular irritation ............................................................................ 283 Skin sensitization.......................................................................... 283 Short-term studies of toxicity ............................................................ 284 Long-term studies of toxicity and carcinogenicity............................ 298 Genotoxicity ....................................................................................... 301 Reproductive toxicity ......................................................................... 302 Multigeneration studies ................................................................ 302 Developmental toxicity................................................................. 303 Special studies.................................................................................... 309 Neurotoxicity ................................................................................ 309 Mechanistic studies ...................................................................... 309 Comparison with other members of the strobilurin class of fungicides ................................................................................ 311 Comments...................................................................................................... 312 Toxicological evaluation................................................................................ 314 References ..................................................................................................... 316